HANXBIO-B Buys Back 22,600 H Shares at Average HK$32.09; Treasury Stock Reaches 547,300 Shares

Bulletin Express05-11

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share repurchase of 22,600 H shares on 11 May 2026 via on-market transactions on the Hong Kong Stock Exchange.

The buyback was executed within a price range of HK$31.86 to HK$32.30 per share, with a volume-weighted average repurchase price of HK$32.09. The total consideration amounted to HK$0.73 million.

Following the transaction, HANXBIO-B’s issued share capital (excluding treasury shares) decreased from 135.69 million to 135.67 million shares, representing a 0.02% reduction. Treasury shares increased to 547,300, while the overall issued share count remained unchanged at 136.22 million shares.

The repurchase forms part of the mandate approved by shareholders on 12 February 2026, which authorises the company to repurchase up to 13.62 million shares. Cumulative repurchases under this mandate now total 547,300 shares, equivalent to 0.40% of the company’s issued share capital on the mandate date.

In line with Hong Kong Listing Rules, the company is subject to a 30-day moratorium on new share issues, sales or transfers of treasury shares until 10 June 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153210622?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-11 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153210622","market":"us","top_or_hot":-1,"title":"HANXBIO-B Buys Back 22,600 H Shares at Average HK$32.09; Treasury Stock Reaches 547,300 Shares","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share repurchase of 22,600 H shares on 11 May 2026 via on-market transactions on the Hong Kong Stock Exchange.</p>\n<p>The buyback was executed within a price range of HK$31.86 to HK$32.30 per share, with a volume-weighted average repurchase price of HK$32.09. The total consideration amounted to HK$0.73 million.</p>\n<p>Following the transaction, HANXBIO-B’s issued share capital (excluding treasury shares) decreased from 135.69 million to 135.67 million shares, representing a 0.02% reduction. Treasury shares increased to 547,300, while the overall issued share count remained unchanged at 136.22 million shares.</p>\n<p>The repurchase forms part of the mandate approved by shareholders on 12 February 2026, which authorises the company to repurchase up to 13.62 million shares. Cumulative repurchases under this mandate now total 547,300 shares, equivalent to 0.40% of the company’s issued share capital on the mandate date.</p>\n<p>In line with Hong Kong Listing Rules, the company is subject to a 30-day moratorium on new share issues, sales or transfers of treasury shares until 10 June 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANXBIO-B Buys Back 22,600 H Shares at Average HK$32.09; Treasury Stock Reaches 547,300 Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANXBIO-B Buys Back 22,600 H Shares at Average HK$32.09; Treasury Stock Reaches 547,300 Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-11 19:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share repurchase of 22,600 H shares on 11 May 2026 via on-market transactions on the Hong Kong Stock Exchange.</p>\n<p>The buyback was executed within a price range of HK$31.86 to HK$32.30 per share, with a volume-weighted average repurchase price of HK$32.09. The total consideration amounted to HK$0.73 million.</p>\n<p>Following the transaction, HANXBIO-B’s issued share capital (excluding treasury shares) decreased from 135.69 million to 135.67 million shares, representing a 0.02% reduction. Treasury shares increased to 547,300, while the overall issued share count remained unchanged at 136.22 million shares.</p>\n<p>The repurchase forms part of the mandate approved by shareholders on 12 February 2026, which authorises the company to repurchase up to 13.62 million shares. Cumulative repurchases under this mandate now total 547,300 shares, equivalent to 0.40% of the company’s issued share capital on the mandate date.</p>\n<p>In line with Hong Kong Listing Rules, the company is subject to a 30-day moratorium on new share issues, sales or transfers of treasury shares until 10 June 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1153210622","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153210622","pubTimestamp":1778499827,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share repurchase of 22,600 H shares on 11 May 2026 via on-market transactions on the Hong Kong Stock Exchange. The buyback was...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"瀚讯生物-B回购2.26万股H股均价32.09港元；库存股达到547,300股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a share repurchase of 22,600 H shares on 11 May 2026 via on-market transactions on the Hong Kong Stock Exchange.\nThe buyback was executed within a price range of HK$31.86 to HK$32.30 per share, with a volume-weighted average repurchase price of HK$32.09. The total consideration amounted to HK$0.73 million.\nFollowing the transaction, HANXBIO-B’s issued share capital (excluding treasury shares) decreased from 135.69 million to 135.67 million shares, representing a 0.02% reduction. Treasury shares increased to 547,300, while the overall issued share count remained unchanged at 136.22 million shares.\nThe repurchase forms part of the mandate approved by shareholders on 12 February 2026, which authorises the company to repurchase up to 13.62 million shares. Cumulative repurchases under this mandate now total 547,300 shares, equivalent to 0.40% of the company’s issued share capital on the mandate date.\nIn line with Hong Kong Listing Rules, the company is subject to a 30-day moratorium on new share issues, sales or transfers of treasury shares until 10 June 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153210622","isCrawlerRequest":true}